The FDA has accepted the new drug application (NDA) for SH 201, the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers
Foundation Medicine, Inc. announced that the FDA approved FoundationOne Liquid CDx, the Company’s comprehensive pan-tumor liquid biopsy test.
The FDA has approved Gammagard Liquid 10% [Immune Globulin Infusion (Human)] as a treatment for Mmultifocal Motor Neuropathy (MMN). This is...
Additional analyses from a negative Phase III clinical trial of Gammagard Liquid/Kiovig (intravenous immunoglobulin), from Baxter, in people with mild...
Rare Disease Therapeutics, Inc. the producer of orphan pharmaceuticals for the treatment of rare diseases, announced that they have received...
Shire plc announces positive topline Phase III results for the SAHARA study, a global, multi-center, randomized, double-blind, placebo-controlled, partial crossover...
Takeda announced that the FDA has approved Gammagard Liquid[Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
Eton Pharma announced that the FDA declined to approve its anti-seizure drug lamotrigine.
Bio Products Laboratory announced that the FDA has approved Gammaplex 10% (immune globulin intravenous [human], 10% liquid) for the treatment...
Limited understanding of ovarian cancer (OC) genome portrait has hindered the therapeutic advances. The serial monitoring of tumor genotypes is becoming increasingly attainable with circulating cell-free DNA (cf-DNA)...